Cargando…
Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were anal...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896903/ https://www.ncbi.nlm.nih.gov/pubmed/29649230 http://dx.doi.org/10.1371/journal.pone.0194924 |
_version_ | 1783313882300809216 |
---|---|
author | Putcha, Nirupama Paul, Gabriel G. Azar, Antoine Wise, Robert A. O’Neal, Wanda K. Dransfield, Mark T. Woodruff, Prescott G. Curtis, Jeffrey L. Comellas, Alejandro P. Drummond, M. Bradley Lambert, Allison A. Paulin, Laura M. Fawzy, Ashraf Kanner, Richard E. Paine, Robert Han, MeiLan K. Martinez, Fernando J. Bowler, Russell P. Barr, R. Graham Hansel, Nadia N. |
author_facet | Putcha, Nirupama Paul, Gabriel G. Azar, Antoine Wise, Robert A. O’Neal, Wanda K. Dransfield, Mark T. Woodruff, Prescott G. Curtis, Jeffrey L. Comellas, Alejandro P. Drummond, M. Bradley Lambert, Allison A. Paulin, Laura M. Fawzy, Ashraf Kanner, Richard E. Paine, Robert Han, MeiLan K. Martinez, Fernando J. Bowler, Russell P. Barr, R. Graham Hansel, Nadia N. |
author_sort | Putcha, Nirupama |
collection | PubMed |
description | BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were analyzed from 1,049 COPD participants from the observational cohort study SPIROMICS (535 (51%) women; mean age 66.1 (SD 7.8), 338 (32%) current smokers) who had baseline serum IgA measured using the Myriad RBM biomarker discovery platform. Exacerbation data was collected prospectively (mean 944.3 (SD 281.3) days), and adjusted linear, logistic and zero-inflated negative binomial regressions were performed. RESULTS: Mean IgA was 269.1 mg/dL (SD 150.9). One individual had deficient levels of serum IgA (<7 mg/dL) and 25 (2.4%) had IgA level ≤70 mg/dL. Participants with IgA ≤70 mg/dL were younger (62 vs. 66 years, p = 0.01) but otherwise similar to those with higher IgA. In adjusted models, IgA ≤70 mg/dL was associated with higher exacerbation incidence rates (IRR 1.71, 95% CI 1.01–2.87, p = 0.044) and greater risk for any severe exacerbation (OR 2.99, 95% CI 1.30–6.94, p = 0.010). In adjusted models among those in the lowest decile (<120 mg/dL), each 10 mg/dL decrement in IgA (analyzed continuously) was associated with more exacerbations during follow-up (β 0.24, 95% CI 0.017–0.46, p = 0.035). CONCLUSIONS: Subnormal serum IgA levels were associated with increased risk for acute exacerbations, supporting mildly impaired IgA levels as a contributing factor in COPD morbidity. Additionally, a dose-response relationship between lower serum IgA and number of exacerbations was found among individuals with serum IgA in the lowest decile, further supporting the link between serum IgA and exacerbation risk. Future COPD studies should more comprehensively characterize immune status to define the clinical relevance of these findings and their potential for therapeutic correction. |
format | Online Article Text |
id | pubmed-5896903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58969032018-05-04 Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS Putcha, Nirupama Paul, Gabriel G. Azar, Antoine Wise, Robert A. O’Neal, Wanda K. Dransfield, Mark T. Woodruff, Prescott G. Curtis, Jeffrey L. Comellas, Alejandro P. Drummond, M. Bradley Lambert, Allison A. Paulin, Laura M. Fawzy, Ashraf Kanner, Richard E. Paine, Robert Han, MeiLan K. Martinez, Fernando J. Bowler, Russell P. Barr, R. Graham Hansel, Nadia N. PLoS One Research Article BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were analyzed from 1,049 COPD participants from the observational cohort study SPIROMICS (535 (51%) women; mean age 66.1 (SD 7.8), 338 (32%) current smokers) who had baseline serum IgA measured using the Myriad RBM biomarker discovery platform. Exacerbation data was collected prospectively (mean 944.3 (SD 281.3) days), and adjusted linear, logistic and zero-inflated negative binomial regressions were performed. RESULTS: Mean IgA was 269.1 mg/dL (SD 150.9). One individual had deficient levels of serum IgA (<7 mg/dL) and 25 (2.4%) had IgA level ≤70 mg/dL. Participants with IgA ≤70 mg/dL were younger (62 vs. 66 years, p = 0.01) but otherwise similar to those with higher IgA. In adjusted models, IgA ≤70 mg/dL was associated with higher exacerbation incidence rates (IRR 1.71, 95% CI 1.01–2.87, p = 0.044) and greater risk for any severe exacerbation (OR 2.99, 95% CI 1.30–6.94, p = 0.010). In adjusted models among those in the lowest decile (<120 mg/dL), each 10 mg/dL decrement in IgA (analyzed continuously) was associated with more exacerbations during follow-up (β 0.24, 95% CI 0.017–0.46, p = 0.035). CONCLUSIONS: Subnormal serum IgA levels were associated with increased risk for acute exacerbations, supporting mildly impaired IgA levels as a contributing factor in COPD morbidity. Additionally, a dose-response relationship between lower serum IgA and number of exacerbations was found among individuals with serum IgA in the lowest decile, further supporting the link between serum IgA and exacerbation risk. Future COPD studies should more comprehensively characterize immune status to define the clinical relevance of these findings and their potential for therapeutic correction. Public Library of Science 2018-04-12 /pmc/articles/PMC5896903/ /pubmed/29649230 http://dx.doi.org/10.1371/journal.pone.0194924 Text en © 2018 Putcha et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Putcha, Nirupama Paul, Gabriel G. Azar, Antoine Wise, Robert A. O’Neal, Wanda K. Dransfield, Mark T. Woodruff, Prescott G. Curtis, Jeffrey L. Comellas, Alejandro P. Drummond, M. Bradley Lambert, Allison A. Paulin, Laura M. Fawzy, Ashraf Kanner, Richard E. Paine, Robert Han, MeiLan K. Martinez, Fernando J. Bowler, Russell P. Barr, R. Graham Hansel, Nadia N. Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title | Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title_full | Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title_fullStr | Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title_full_unstemmed | Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title_short | Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS |
title_sort | lower serum iga is associated with copd exacerbation risk in spiromics |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896903/ https://www.ncbi.nlm.nih.gov/pubmed/29649230 http://dx.doi.org/10.1371/journal.pone.0194924 |
work_keys_str_mv | AT putchanirupama lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT paulgabrielg lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT azarantoine lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT wiseroberta lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT onealwandak lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT dransfieldmarkt lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT woodruffprescottg lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT curtisjeffreyl lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT comellasalejandrop lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT drummondmbradley lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT lambertallisona lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT paulinlauram lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT fawzyashraf lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT kannerricharde lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT painerobert lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT hanmeilank lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT martinezfernandoj lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT bowlerrussellp lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT barrrgraham lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT hanselnadian lowerserumigaisassociatedwithcopdexacerbationriskinspiromics AT lowerserumigaisassociatedwithcopdexacerbationriskinspiromics |